"GENEART provides integrated system solutions for DNA engineering and processing based on the gene synthesis technology platform to deliver improved drugs and biotech products. The services portfolio ranges from the production of optimized synthetic genes and the generation of gene variants and gene libraries in combinatorial biology (gene evolution) right through to the production of DNA-based agents.
"Markets and business areas
"GENEART's services are utilized by pharmaceutical and biotech companies, and research institutes on the following markets:
Red Biotechnology:
DNA-based drugs and recombinant vaccines
Protein drugs
White Biotechnology:
Biocatalysts (enzymes, e.g. for industrial processes and consumer goods)
Green Biotechnology
Production of biopharmaceuticals in plants
Transgenic plants
Hugging Face’s New AI Biology Model Lets You Chat With DNA
The new open-source model speaks the language of DNA and can help researchers understand the effects of any changes on gene activity and health.
Emily Mullin
Anthropic Says It Will Revolutionize Biology—Some Day
In breathless press releases and posts, the company has touted its models’ ability to deliver scientific breakthroughs. But its IPO filing taps the brakes on just how fast its AI will lead to big discoveries.
Emily Mullin
A New Anti-Aging Drug Looks to Turn Back the Clock on Skin Age
After four weeks of using the cream, participants lowered the biological age of their skin by about two years on average.
Emily Mullin
Why AI Isn’t Ready to Tackle Our Convoluted Genomes
The DNA inside our cells isn’t just a series of instructions, but something far more dynamic. Like scientists, AI models don't yet have the data to properly decode it.
Philip Ball
Life Is Asymmetric. The Scientists Who Figured Out Why Won the 2026 Nobel Prize in Chemistry
Henri Kagan and Kensō Soai designed chemical reactions producing only one of the two mirror-image forms of a molecule—an important finding for the synthesis of pharmaceuticals and other biological substances.
Fernanda González
Cool, Cool, Cool, Palmer Luckey and Ben Lamm Made a Genetically Modified Military Dog Startup
Warhound came out of stealth on Wednesday with $200 million in funding and a mission to create “elite working dogs” equipped with "advanced body armor."
Kate Knibbs
The Science Behind the Nobel-Winning Technology That Controls Neurons With Light
Optogenetics revolutionized neuroscience, but its origins come from an entirely brainless organism—an alga.
Fernanda González
Your Next Great Read Might Be Certified ‘Organic’
Amid a sea of AI writing slop, a new stamp for “organic literature” will help readers to pick out books authored by real, corn-fed, free-range humans.
Joel Khalili
Anthropic’s IPO Prospectus Reveals What’s Under the Hood
Anthropic on Monday filed documents ahead of a blockbuster IPO that offers insight into the company’s financials, risk factors, and views on the future of AI.
Joel Khalili
OpenAI Invests in Startup That Uses Brain Implants to Detect Cancer
It’s the latest in a growing wave of bets that AI companies are making on brain data.
Emily Mullin
How Elizabeth Holmes Tricked WIRED—and Everyone Else
WIRED was the first magazine to cover Theranos and its enticing billionaire founder. There were warning signs even then.
Adam Rogers
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Fernanda González